Defense World
05 Sept 2026, 08:21 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Abbott Laboratories reported quarterly revenue of $12.59 billion and EPS of $1.31, beating analyst expectations on both metrics. — Actual financial outperformance against consensus estimates typically drives positive price action.
+0.40The company provided Q3 2026 guidance of $1.38–$1.46 EPS and FY 2026 guidance of $5.45–$5.60 EPS. — Forward-looking guidance provides the primary basis for valuation models and investor expectations.
+0.30Wolfe Research upgraded Abbott Laboratories from 'peer perform' to 'outperform' with a $130 price target. — Analyst upgrades from neutral to bullish ratings can trigger institutional buying.
+0.20Continue reading
5 related stories
Search tags
Benjamin Edwards Inc. reduced its position in Abbott Laboratories by 35.6% during the second quarter. — Significant trimming by an institutional holder can signal a lack of confidence in near-term upside, though the overall impact is mitigated by other buyers.
UBS Group and Goldman Sachs Group both lowered their price targets for ABT to $125 and $113 respectively. — Downward revisions of price targets generally put modest downward pressure on the stock price.
-0.10Which stocks this story touches
Positive earnings beat, revenue growth, multiple analyst upgrades/buy ratings, and dividend payments offset one large institutional sell-off.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
